KR20220148237A - 항-axl 항체 및 조성물 - Google Patents

항-axl 항체 및 조성물 Download PDF

Info

Publication number
KR20220148237A
KR20220148237A KR1020227033462A KR20227033462A KR20220148237A KR 20220148237 A KR20220148237 A KR 20220148237A KR 1020227033462 A KR1020227033462 A KR 1020227033462A KR 20227033462 A KR20227033462 A KR 20227033462A KR 20220148237 A KR20220148237 A KR 20220148237A
Authority
KR
South Korea
Prior art keywords
amino acid
seq
acid sequence
antibody
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227033462A
Other languages
English (en)
Korean (ko)
Inventor
토르벤 그제팅
트린 린드스테드
안톤 윌러
앤 워사에
에바 마리아 칼슨 멜란더
야누스 슈 야콥센
랜디 웨스 한센
Original Assignee
심포젠 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 심포젠 에이/에스 filed Critical 심포젠 에이/에스
Publication of KR20220148237A publication Critical patent/KR20220148237A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020227033462A 2020-02-28 2021-02-26 항-axl 항체 및 조성물 Pending KR20220148237A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062982852P 2020-02-28 2020-02-28
US62/982,852 2020-02-28
PCT/IB2021/051636 WO2021171257A1 (en) 2020-02-28 2021-02-26 Anti-axl antibodies and compositions

Publications (1)

Publication Number Publication Date
KR20220148237A true KR20220148237A (ko) 2022-11-04

Family

ID=75426640

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227033462A Pending KR20220148237A (ko) 2020-02-28 2021-02-26 항-axl 항체 및 조성물

Country Status (17)

Country Link
US (1) US11807688B2 (https=)
EP (1) EP4110824A1 (https=)
JP (1) JP7748377B2 (https=)
KR (1) KR20220148237A (https=)
CN (1) CN115210263A (https=)
AR (1) AR121441A1 (https=)
AU (1) AU2021225490B2 (https=)
BR (1) BR112022015977A2 (https=)
CA (1) CA3170975A1 (https=)
CL (1) CL2022002259A1 (https=)
CO (1) CO2022012159A2 (https=)
IL (1) IL295596A (https=)
MX (1) MX2022010670A (https=)
MY (1) MY209381A (https=)
PE (1) PE20221783A1 (https=)
PH (1) PH12022552041A1 (https=)
WO (1) WO2021171257A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026001894A1 (zh) * 2024-06-24 2026-01-02 上海医药集团生物治疗技术有限公司 靶向axl的嵌合抗原受体及其用途
CN119591720B (zh) * 2024-11-28 2026-02-10 北京大学深圳研究生院 抗人axl抗体、基因及其应用
CN119912586B (zh) * 2024-12-31 2025-09-30 四川省肿瘤医院 基于受体酪氨酸激酶家族axl改造的嵌合抗原受体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
CA2706549A1 (en) * 2007-11-15 2009-05-22 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
BRPI1013428A2 (pt) * 2009-05-11 2019-07-02 U3 Pharma Gmbh anticorpos humanizados para axl
BR112012027995A2 (pt) * 2010-06-18 2017-01-10 Genentech Inc anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl
MX2015005757A (es) * 2012-11-08 2015-11-18 Hoffmann La Roche Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
JP6931609B2 (ja) 2014-12-18 2021-09-08 ベルゲン テクノロジオーヴァーフォリング エイエス 抗Ａｘｌアンタゴニスト抗体
CN108368171A (zh) * 2015-07-10 2018-08-03 根马布股份公司 用于癌症治疗的axl特异性抗体-药物缀合物
PL3368572T3 (pl) * 2015-10-02 2022-09-12 Symphogen A/S Przeciwciała anty-PD-1 oraz kompozycje
TN2018000333A1 (en) * 2016-04-12 2020-01-16 Symphogen As Anti-tim-3 antibodies and compositions
GB201610902D0 (en) * 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
CA3095986A1 (en) 2018-04-10 2019-10-17 Genmab A/S Axl-specific antibodies for cancer treatment

Also Published As

Publication number Publication date
PH12022552041A1 (en) 2023-11-29
BR112022015977A2 (pt) 2022-10-11
PE20221783A1 (es) 2022-11-16
WO2021171257A1 (en) 2021-09-02
CN115210263A (zh) 2022-10-18
EP4110824A1 (en) 2023-01-04
MX2022010670A (es) 2022-09-23
AR121441A1 (es) 2022-06-08
IL295596A (en) 2022-10-01
AU2021225490B2 (en) 2025-11-27
CA3170975A1 (en) 2021-09-02
US11807688B2 (en) 2023-11-07
JP7748377B2 (ja) 2025-10-02
CL2022002259A1 (es) 2023-04-14
TW202146455A (zh) 2021-12-16
JP2023515821A (ja) 2023-04-14
CO2022012159A2 (es) 2022-10-31
AU2021225490A1 (en) 2022-09-15
US20210269532A1 (en) 2021-09-02
MY209381A (en) 2025-07-04

Similar Documents

Publication Publication Date Title
TWI859319B (zh) 抗ｃｄ７３抗體及組合物
JP7679399B2 (ja) 抗ｆｌｔ３抗体及び組成物
US12012450B2 (en) Anti-NKG2A antibodies and compositions
JP7748377B2 (ja) 抗ａｘｌ抗体及び組成物
US20210214454A1 (en) Anti-cd40 antibodies and compositions
RU2837590C1 (ru) Антитела против axl и композиции
RU2837590C9 (ru) Антитела против axl и композиции
TWI920062B (zh) 抗axl抗體及組合物
RU2836004C1 (ru) Антитела и композиции против flt3
HK40081002A (en) Anti-axl antibodies and compositions
HK40106092A (zh) 抗nkg2a抗体和组合物
EA052808B1 (ru) Антитела и композиции против flt3

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220926

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application